Eliska Zelinkova

Eliska Zelinkova

Auto-generated profile, based on publicly available information

Eliska Zelinkova

Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Mediators of Inflammation
Verified
Journal Article
Open access
PCPetra Chalova
Petra Chalova
BJBarbora Jankovicova
Barbora Jankovicova
VDVeronika Dvorakova
Veronika Dvorakova
EZEliska Zelinkova
Eliska Zelinkova
ZBZuzana Bilkova
Zuzana Bilkova
Ludovit SkultetyLudovit Skultety
Ludovit Skultety
Spontaneous tumor regression is a recognized phenomenon across various cancer types. Recent research emphasizes the alterations in autoantibodies against carbonic anhydrase I (CA I) (anti‐CA I) levels as potential prognostic markers for various malignancies. Particularly, autoantibodies targeting CA I and II appear to induce cellular damage by inhibiting their respective protein’s catalytic functions. Our study illuminates the profound impact of anti‐CA I autoantibodies from patient serum on the esterase activity of human CA I, exhibiting inhibitory effects akin to the acetazolamide inhibitor. Concurrently, our newly synthesized mouse monoclonal IgG antibody, mAb 2B8, against human CA I showcased a potent inhibitory action. An in‐depth exploration into mAb 2B8′s binding dynamics with its target enzyme was undertaken. Leveraging epitope extraction and phage display library techniques, we identified the amino acid sequence DFWTYP (positions 191–196 of CA I) as crucial for mAb 2B8′s interaction. In 3‐D structural analysis, this sequence is spatially adjacent to a previously identified epitope (DFWTYP) that interacts with patient‐derived autoantibodies. Critically, mAb 2B8 demonstrated an ability to infiltrate eukaryotic cells, engaging specifically with its intracytoplasmic target. This positions mAb 2B8 as a promising model for future studies aimed at tumor cell eradication.